Compare DCO & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCO | NRIX |
|---|---|---|
| Founded | 1849 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 1995 | 2020 |
| Metric | DCO | NRIX |
|---|---|---|
| Price | $137.98 | $16.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $153.60 | $30.50 |
| AVG Volume (30 Days) | 162.7K | ★ 793.6K |
| Earning Date | 05-12-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $824,730,000.00 | $76,987,000.00 |
| Revenue This Year | $7.40 | N/A |
| Revenue Next Year | $8.59 | $48.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 4.85 | ★ 99.31 |
| 52 Week Low | $66.24 | $8.20 |
| 52 Week High | $148.82 | $22.50 |
| Indicator | DCO | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 49.80 | 52.12 |
| Support Level | $135.26 | $16.02 |
| Resistance Level | $143.08 | $16.71 |
| Average True Range (ATR) | 6.07 | 0.73 |
| MACD | -0.91 | -0.06 |
| Stochastic Oscillator | 33.88 | 46.38 |
Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.